See the latest drugs approved for the treatment of chronic hepatitis C infection.
When the drug Sovaldi (sofusbuvir) was first introduced into the market in September 2014, it marked not only a sea change in how we treated chronic hepatitis C (HCV) infection, it made obsolete earlier generation medications which demonstrated no where near the efficacy of this newer direct acting antiviral (DAA). Among them, Vertex Pharmaceutical’s Incivek (telapravir) and Merck’s Victrelis (boceprevir), both of which were voluntarily discontinued in October 2014 and December 2015, respectively.
Following fast on Sovaldi’s heels were six additional DAA molecules and a number of combination pills able to treat an ever-widening range of HCV genotypes—and with shorter treatment duration and far fewer side effects.
With cure rates well exceeding 95% in many cases, the only challenge now is how to effectively expand access to the 130-150 million people chronically infected with HCV worldwide (including 9% of the HIV-infected population believed to be co-infected with HCV).
The following DAAs are listed by order of their FDA approval dates:
Read Full Article: List of Hepatitis C Drugs – Direct Acting Antivirals